Granting of Key Patent in Europe and Japan
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Amplia Therapeutics Ltd. has announced the granting of a key patent in Europe and Japan for its FAK inhibitor narmafotinib, which describes a specific chemical form of the drug. The patent was granted by the Japanese Patent Office and is expected to be granted in Europe shortly thereafter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Additional Patient Response in Pancreatic Cancer Trial
- Sustained Reduction in Tumour Size Seen In Pancreatic Trial
- First 26 Patients recruited in Phase 2A ACCENT Trial
- Preliminary Final Report and Annual Report YE 31 March 2024
- $4.27m Offer Successfully Completed and ACCENT Trial Update
Later from Amplia Therapeutics
- Amplia Receives R&D Tax Rebate Totalling $3.2 Million
- Fifth Confirmed Response in ACCENT Trial
- FDA Fast Track Designation for Narmafotinib
- Sixth Confirmed Response in Pancreatic Cancer Trial
- Interim Data From Accent Pancreatic Cancer Trial
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics